Audicin raises $1.9M to make nervous system regulation a built-in layer for wearables and partner apps
Summary
Audicin raised $1.9M to develop biosignal processing technology enabling any wearable to deliver personalized nervous system interventions based on continuous physiological monitoring. Their platform-as-a-service model targets OEM partnerships with consumer wearable companies rather than direct-to-consumer sales, aiming to be the "nervous system regulation engine" inside third-party devices. The $1.9M will fund the technical integration with two OEM partners.
Why it matters
Audicin's OEM platform strategy — making nervous system regulation a feature inside existing wearables rather than a separate device — is the correct go-to-market for a $1.9M company. Licensing to existing consumer wearable brands bypasses the cold-start problem of building a new device category and leverages existing distribution channels.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial